Location: Endemic Poultry Viral Diseases Research
Title: Review of poultry recombinant vector vaccinesAuthor
HEIN, RUUD - Consultant | |
KOOPMAN, RIK - Msd | |
GARCIA, MARICARMEN - University Of Georgia | |
ARMOUR, NATALIE - Mississippi State University | |
Dunn, John | |
BARBOSA, TAYLOR - Msd | |
MARTINEZ, ALGIS - Cobb-Vantress, Inc |
Submitted to: Avian Diseases
Publication Type: Peer Reviewed Journal Publication Acceptance Date: 6/1/2021 Publication Date: 9/1/2021 Publication URL: https://handle.nal.usda.gov/10113/7529156 Citation: Hein, R., Koopman, R., Garcia, M., Armour, N., Dunn, J.R., Barbosa, T., Martinez, A. 2021. Review of poultry recombinant vector vaccines. Avian Diseases. 65(3):438–452. https://doi.org/10.1637/0005-2086-65.3.438. DOI: https://doi.org/10.1637/0005-2086-65.3.438 Interpretive Summary: The control of poultry diseases has relied heavily on the use of many live and killed vaccines. However, over the last 30 years, new technology has been used to generate new poultry vaccines. Fowl poxvirus (FPV) and turkey herpesvirus (HVT) are two common poultry vaccines that have recently been utilized as vectors to construct vaccines for poultry that can protect against multiple viruses. Using these two vectors, more than 15 viral vector vaccines against five other important poultry viruses have been developed and are commercially available. This review will be focused on current knowledge about the safety and efficacy of viral vectored vaccines, and the mechanisms by which they facilitate the control of multiple diseases. In addition, the development of new vaccines using novel vectors is discussed. Technical Abstract: The control of poultry diseases has relied heavily on the use of many live and inactivated vaccines. However, over the last 30 years, recombinant DNA technology has been used to generate many novel poultry vaccines. Fowl poxvirus (FPV) and turkey herpesvirus (HVT) are the two main vectors currently utilized to construct recombinant vaccines for poultry. Using these two vectors, more than 15 recombinant viral vector vaccines against Newcastle disease (ND), infectious laryngotracheitis (ILT), infectious bursal disease (IBD), avian influenza (AI), and Mycoplasma gallisepticum (MG) have been developed and are commercially available. This review will be focused on current knowledge about the safety and efficacy of recombinant viral vectored vaccines, and the mechanisms by which they facilitate the control of multiple diseases. In addition, the development of new recombinant vaccines using novel vectors will be briefly discussed. |